ArticleBMC medicine2023

PARP inhibitor exerts an anti-tumor effect via LMO2 and synergizes with cisplatin in natural killer/T cell lymphoma.

Jiazhuo Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.